DreaMed Diabetes Technology to Be Integrated into Medtronic’s Insulin Pumps

DreaMed Diabetes announced Monday that it has licensed artificial pancreas technology — the GlucoSitter — to Medtronic for use in the latter’s insulin pumps. Under the deal, DreaMed will receive royalties from each device equipped with the technology that Medtronic develops and markets, the Israel-based company said.

Utilizing the MD-Logic Artificial Pancreas algorithm, the GlucoSitter controls glucose levels through an automated delivery system that imitates a healthy pancreas. This reduces the risk of low- and high-blood glucose episodes, DreaMed says.

The artificial pancreas technology will mitigate part of the individual glucose management burden, said Alejandro Galindo,vice president and general manager of Medtronic’s intensive insulin management business. Medtronic has invested $2 million in DreaMed.

FDA clearance and CE Mark approval for the GlucoSitter are being sought.

DreaMed was founded in 2014 to provide diabetes treatment options for type 1 and 2 sufferers. — Jason Scott